NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.22 | 0.15 | -0.02 |
| FCF Yield | -0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -20.22 | -9.80 | -12.84 | -11.82 |
| Quality | ||||
| ROIC | 452.02% | 452.02% | -64.90% | 75.28% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 0.28 | 1.87 | 0.15 |
| Interest Coverage | -276.00 | -276.00 | -59.03 | -51.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |